Study of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukemia.
Moxetumomab pasudotox is an experimental cancer treatment drug. It looks for a marker on the surface of almost all hairy cell leukemia cells. Moxetumomab pasudotox binds to that marker and then goes into the cell releasing a toxin which kills the cell. In a previous trial it showed activity in relapsed/refractory hairy cell leukemia. This is a phase III multicenter trial designed to confirm these results.
To enroll or if you have questions about participation